临床医学专业-进展性转移性NSCLC免疫治疗.pptxVIP

Helena A. Yu, MD Assistant Attending Department of MedicineMemorial Sloan Kettering Cancer CenterNew York, New York;About These Slides;Faculty Disclosure;Presentation Outline;Compound;;Nivolumab3 mg/kg IV Q2W until PD or unacceptable toxicity (n = 135);20;KEYNOTE-010: Pembrolizumab vs Docetaxel in Advanced PD-L1–Positive NSCLC;0;KEYNOTE-010: OS Subgroup Analysis*;OAK: Atezolizumab vs Docetaxel in Progressive Advanced NSCLC;OAK: Overall Survival;Immunotherapy in EGFR Mutation–Positive Adv NSCLC;IMpower150: Atezolizumab + Carbo/Pac + Bevacizumab in Nonsquamous NSCLC;IMpower150: PFS in EGFR Mu